NgenBio Initiates Clinical Study on Metastatic Breast Cancer Patients with Samsung Seoul Hospital

[Asia Economy Reporter Lee Gwan-joo] EnGen Bio announced on the 4th that, with the support of global pharmaceutical companies Pfizer and Roche, it has partnered with Samsung Medical Center to initiate the 'Young-PALETTA Phase 2 Clinical Trial.'

This study aims to evaluate the efficacy and tolerability of the combination therapy of Talazoparib and Atezolizumab in premenopausal HR+/HER2- metastatic breast cancer patients with homologous recombination deficiency (HRD). Led by Professor Park Yeon-hee of the Hematology-Oncology Department at Samsung Medical Center, 14 major hospitals nationwide are participating.

EnGen Bio conducts genetic sequencing analysis of patients to select candidates for the clinical trial. EnGen Bio's SolidActus product can simultaneously analyze about 100 genes, including 35 homologous recombination deficiency genes.

Upon receiving the results, Samsung Medical Center will analyze the mutation profiles of premenopausal HR-positive patients with gene mutations or homologous recombination deficiency scars and will prescribe medication to the selected clinical trial participants, subsequently monitoring their progress.

Kim Kwang-jung, Director of EnGen Bio's Corporate Research Institute, stated, “This research service, following the large-scale hereditary breast cancer epidemiology clinical research collaboration with Samsung Medical Center since last year, once again recognizes our company's NGS companion diagnostic development capabilities. We will work closely with the research team to contribute to improving treatment outcomes for domestic metastatic breast cancer patients.”